Free Trial

MN Wealth Advisors LLC Buys 12,728 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Viking Therapeutics logo with Medical background

MN Wealth Advisors LLC increased its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 215.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,628 shares of the biotechnology company's stock after purchasing an additional 12,728 shares during the period. MN Wealth Advisors LLC's holdings in Viking Therapeutics were worth $450,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in VKTX. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Viking Therapeutics by 7.4% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after buying an additional 345 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Viking Therapeutics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock valued at $1,164,000 after purchasing an additional 353 shares during the last quarter. WealthTrust Asset Management LLC grew its stake in shares of Viking Therapeutics by 6.7% during the fourth quarter. WealthTrust Asset Management LLC now owns 6,923 shares of the biotechnology company's stock valued at $279,000 after purchasing an additional 437 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 536 shares during the last quarter. Finally, Xponance Inc. grew its stake in shares of Viking Therapeutics by 4.5% during the fourth quarter. Xponance Inc. now owns 14,024 shares of the biotechnology company's stock valued at $564,000 after purchasing an additional 610 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on VKTX shares. The Goldman Sachs Group started coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target on the stock. Morgan Stanley decreased their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Truist Financial reissued a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. HC Wainwright reissued a "buy" rating and set a $102.00 price target on shares of Viking Therapeutics in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald raised shares of Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $87.15.

Check Out Our Latest Research Report on Viking Therapeutics

Insider Transactions at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now directly owns 1,240 shares in the company, valued at approximately $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company's stock.

Viking Therapeutics Stock Down 1.0%

VKTX stock traded down $0.27 during midday trading on Friday, reaching $26.01. The company's stock had a trading volume of 2,953,670 shares, compared to its average volume of 4,041,002. Viking Therapeutics, Inc. has a 52 week low of $18.92 and a 52 week high of $81.73. The stock has a market cap of $2.92 billion, a PE ratio of -22.62 and a beta of 0.65. The business's 50-day simple moving average is $26.90 and its 200-day simple moving average is $31.13.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). Viking Therapeutics's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.26) EPS. As a group, equities analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Viking Therapeutics Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Should You Invest $1,000 in Viking Therapeutics Right Now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines